Literature DB >> 32757369

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.

Paul A VanderLaan, Deepa Rangachari, Daniel B Costa.   

Abstract

Entities:  

Year:  2020        PMID： 32757369      PMCID： PMC7862419          DOI： 10.1002/cncy.22334

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN： 1934-662X            Impact factor:   5.284


× No keyword cloud information.
  12 in total

1.  Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

Authors:  Gregory P Kalemkerian; Navneet Narula; Erin B Kennedy; William A Biermann; Jessica Donington; Natasha B Leighl; Madelyn Lew; James Pantelas; Suresh S Ramalingam; Martin Reck; Anjali Saqi; Michael Simoff; Navneet Singh; Baskaran Sundaram
Journal:  J Clin Oncol       Date:  2018-02-05       Impact factor: 44.544

Review 2.  Invited review-next-generation sequencing: a modern tool in cytopathology.

Authors:  Sinchita Roy-Chowdhuri; Pasquale Pisapia; Manuel Salto-Tellez; Spasenija Savic; Mariantonia Nacchio; Dario de Biase; Giovanni Tallini; Giancarlo Troncone; Fernando Schmitt
Journal:  Virchows Arch       Date:  2019-03-15       Impact factor: 4.064

3.  From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

Authors:  Deepa Rangachari; Daniel B Costa
Journal:  J Clin Oncol       Date:  2019-06-02       Impact factor: 44.544

4.  The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer.

Authors:  Matthew P Smeltzer; Murry W Wynes; Sylvie Lantuejoul; Ross Soo; Suresh S Ramalingam; Marileila Varella-Garcia; Meghan Meadows Taylor; Kristin Richeimer; Kelsey Wood; Kristen E Howell; Mercedes Lilana Dalurzo; Enriqueta Felip; Gina Hollenbeck; Keith Kerr; Edward S Kim; Clarissa Mathias; Jose Pacheco; Pieter Postmus; Charles Powell; Masahiro Tsuboi; Ignacio I Wistuba; Heather A Wakelee; Chandra P Belani; Giorgio V Scagliotti; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2020-05-20       Impact factor: 15.609

5.  Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

Authors:  Marcello DiStasio; Yigu Chen; Deepa Rangachari; Daniel B Costa; Yael K Heher; Paul A VanderLaan
Journal:  Clin Lung Cancer       Date:  2017-03-14       Impact factor: 4.785

6.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Authors:  Natasha B Leighl; Ray D Page; Victoria M Raymond; Davey B Daniel; Stephen G Divers; Karen L Reckamp; Miguel A Villalona-Calero; Daniel Dix; Justin I Odegaard; Richard B Lanman; Vassiliki A Papadimitrakopoulou
Journal:  Clin Cancer Res       Date:  2019-04-15       Impact factor: 12.531

Review 7.  National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important?

Authors:  Lenora A Pluchino; Thomas A D'Amico
Journal:  Ann Thorac Surg       Date:  2020-04-13       Impact factor: 4.330

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

Review 9.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Authors:  Ferdinandos Skoulidis; John V Heymach
Journal:  Nat Rev Cancer       Date:  2019-08-12       Impact factor: 60.716

10.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245
View more
  1 in total

1.  Genome-wide mapping of somatic mutation rates uncovers drivers of cancer.

Authors:  Maxwell A Sherman; Adam U Yaari; Oliver Priebe; Felix Dietlein; Po-Ru Loh; Bonnie Berger
Journal:  Nat Biotechnol       Date:  2022-06-20       Impact factor: 68.164
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.